CN101951768A - 神经原性化合物 - Google Patents

神经原性化合物 Download PDF

Info

Publication number
CN101951768A
CN101951768A CN200880011384XA CN200880011384A CN101951768A CN 101951768 A CN101951768 A CN 101951768A CN 200880011384X A CN200880011384X A CN 200880011384XA CN 200880011384 A CN200880011384 A CN 200880011384A CN 101951768 A CN101951768 A CN 101951768A
Authority
CN
China
Prior art keywords
sugar
compound
gallate
maltose
fructose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880011384XA
Other languages
English (en)
Chinese (zh)
Inventor
J·F·小哈默斯通
M·A·克尔姆
F·H·盖奇
H·范普拉格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mars Inc
Salk Institute for Biological Studies
Original Assignee
Mars Inc
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars Inc, Salk Institute for Biological Studies filed Critical Mars Inc
Publication of CN101951768A publication Critical patent/CN101951768A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880011384XA 2007-02-14 2008-02-13 神经原性化合物 Pending CN101951768A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90123907P 2007-02-14 2007-02-14
US60/901,239 2007-02-14
PCT/US2008/001914 WO2008147483A2 (en) 2007-02-14 2008-02-13 Neurogenic compounds

Publications (1)

Publication Number Publication Date
CN101951768A true CN101951768A (zh) 2011-01-19

Family

ID=39763345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880011384XA Pending CN101951768A (zh) 2007-02-14 2008-02-13 神经原性化合物

Country Status (9)

Country Link
US (1) US20080227829A1 (https=)
EP (2) EP2117306A4 (https=)
JP (1) JP2010518164A (https=)
CN (1) CN101951768A (https=)
AU (1) AU2008257437A1 (https=)
CA (1) CA2677892A1 (https=)
IL (1) IL200383A0 (https=)
RU (1) RU2009134137A (https=)
WO (1) WO2008147483A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473506A4 (en) 2009-09-02 2013-03-06 Canthera Therapeutics Inc COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
US8349832B2 (en) * 2009-09-02 2013-01-08 Canthera Therapeutics Compounds and compositions for treating cancer
US8318737B2 (en) 2009-09-02 2012-11-27 Canthera Therapeutics Inc. Compounds and compositions for treating cancer
WO2011049629A2 (en) 2009-10-22 2011-04-28 Api Genesis, Llc Methods of making and using compositions comprising flavonoids
CN103327971A (zh) 2010-10-22 2013-09-25 Api起源有限责任公司 提高难溶性化合物的溶解度的方法以及制备和使用这类化合物制剂的方法
EP2720693B8 (en) 2011-06-17 2017-05-17 Ludwig Aigner Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders
RU2636463C2 (ru) * 2012-01-17 2017-11-23 Сантори Холдингз Лимитед Новый ген гликозилтрансферазы и его применение
JP6797408B2 (ja) 2014-11-06 2020-12-09 国立大学法人 長崎大学 新規アルツハイマー病治療薬
JP6207545B2 (ja) * 2015-04-30 2017-10-04 丸大食品株式会社 学習記憶能力増強剤
JP6842093B2 (ja) * 2019-08-20 2021-03-17 丸大食品株式会社 学習記憶能力増強剤
JP7754447B2 (ja) * 2021-10-21 2025-10-15 松本 忠昌 ストレスを軽減するための組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317071D0 (en) * 1993-08-17 1993-09-29 Univ Strathclyde Flavonoids
GB9521184D0 (en) * 1995-10-17 1995-12-20 Univ Strathclyde Flavonoids
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
CN1184895C (zh) * 1998-07-16 2005-01-19 阿龙·塔博尔 大豆组合物及其促进健康的应用
EP1115718A1 (en) * 1998-09-24 2001-07-18 Mitsubishi Chemical Corporation Hydroxyflavone derivatives as tau protein kinase 1 inhibitors
US6451837B1 (en) * 1999-09-01 2002-09-17 Andrius Baskys Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
EP1127572A3 (en) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Use of flavones for treating cycloxygenase-2 mediated diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US6472436B1 (en) * 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
JP4633897B2 (ja) * 2000-08-17 2011-02-16 長瀬産業株式会社 神経突起伸長剤
US6733797B1 (en) * 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
WO2002076473A1 (en) * 2001-03-26 2002-10-03 Academy Of Military Medical Sciences Institute Of Pharmacology And Toxicology Quercetin derivative and its medicinal use
DK1417211T3 (da) * 2001-07-27 2007-10-08 Neptune Technologies & Bioress Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse
JP4609875B2 (ja) * 2001-07-31 2011-01-12 有限会社大長企画 健康食品
CN104643057A (zh) * 2002-07-24 2015-05-27 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其用途
AU2003282999A1 (en) * 2002-10-22 2004-05-13 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
WO2005020881A2 (en) * 2003-09-01 2005-03-10 Shanghai Comman Pharmaceutical Co. Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases
KR100610562B1 (ko) * 2004-06-28 2006-08-08 재단법인서울대학교산학협력재단 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물
US20060148727A1 (en) * 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
US7442394B2 (en) * 2005-05-02 2008-10-28 University Of South Florida Combined effects of nutrients on proliferation of stem cells
WO2008011538A2 (en) * 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory

Also Published As

Publication number Publication date
AU2008257437A1 (en) 2008-12-04
CA2677892A1 (en) 2008-12-04
WO2008147483A3 (en) 2009-02-26
EP2478901A3 (en) 2012-11-14
WO2008147483A2 (en) 2008-12-04
EP2117306A2 (en) 2009-11-18
RU2009134137A (ru) 2011-03-27
WO2008147483A9 (en) 2009-04-09
JP2010518164A (ja) 2010-05-27
US20080227829A1 (en) 2008-09-18
WO2008147483A8 (en) 2009-01-15
IL200383A0 (en) 2010-04-29
EP2117306A4 (en) 2010-02-10
EP2478901A2 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
CN101951768A (zh) 神经原性化合物
Odaira et al. Mechanisms underpinning AMP-activated protein kinase-related effects on behavior and hippocampal neurogenesis in an animal model of depression
Khan et al. Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder
Wang et al. Ethanol-mediated facilitation of AMPA receptor function in the dorsomedial striatum: implications for alcohol drinking behavior
US6335361B1 (en) Method of treating benign forgetfulness
US9271966B2 (en) Pharmaceutical compositions for the treatment of movement disorders
US9555055B2 (en) Use of albiflorin and metabolites thereof
Huang et al. The salt-inducible kinases inhibitor HG-9-91-01 exhibits antidepressant-like actions in mice exposed to chronic unpredictable mild stress
Hilal et al. Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies
Wang et al. Serotonin mitigates depression in a rotenone-induced mouse Parkinson’s disease model by inhibiting hippocampal neuronal pyroptosis and neuroinflammation
Othman et al. Combined Ketamine and Midazolam Versus Midazolam Alone for Initial Treatment of Pediatric Generalized Convulsive Status Epilepticus (Ket-Mid Study): A Randomized Controlled Trial
Ara et al. Perspective chapter: Pathophysiology of spinal cord injury and effect of neutraceuticals in providing potential health benefits
CN102247347B (zh) 牛磺酸在制备预防成瘾药物引起的神经细胞损伤的药物中的用途
US20200323809A1 (en) Compounds useful for increasing neurogenesis in neural tissue
Altunkaynak et al. Effects of Methylphenidate and Atomoxetine on Development of the Brain
Sindurakar et al. Potential Synergistic Roles of Ketogenic Diet and Stem Cell Therapy in Parkinson's Disease: A Narrative Review
Abdoulaye et al. Research Article Ketamine Induces Lasting Antidepressant Effects by Modulating the NMDAR/CaMKII-Mediated Synaptic Plasticity of the Hippocampal Dentate Gyrus in Depressive Stroke Model
JP2021011466A (ja) Ａｇｉｑ含有組成物の記憶に関する新たな用途
Novotny et al. Antidepressants and Anticonvulsants/Mood Stabilizers in the Treatment of Autism
Milton Effect of a low dose of ethanol on drug-induced locomotor activity
HK1180966A (en) Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110119